Serina Therapeutics Expands Leadership with Karen J. Wilson
Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its innovative POZ Platform drug delivery technology, has recently welcomed Karen J. Wilson to its Board of Directors.
Welcoming Karen J. Wilson
Serina's Chief Executive Officer, Steve Ledger, expressed enthusiasm about Wilson's appointment, noting, "We are excited to welcome Karen to the Board of Directors. Karen’s financial expertise and deep understanding of the biotech landscape will play a crucial role in guiding our strategic initiatives and delivering transformative therapies to patients.”
Wilson's vast experience spans over thirty years in the life sciences field. She has previously held significant posts, enhancing her expertise in financial leadership. Currently, she also serves on the boards of Connect Biopharma Holdings Limited, Elicio Therapeutics, Inc., and LAVA Therapeutics N.V. Her prior role as Senior Vice President of Finance at Jazz Pharmaceuticals plc involved key financial responsibilities, including serving as Principal Accounting Officer.
Wilson's Vision for Serina
Expressing her excitement about joining Serina, Wilson stated, "I am excited to join Serina at such a pivotal time in its growth. I look forward to working with the talented executive team and fellow board members to help drive the company's vision forward and make a meaningful impact in the lives of patients.” It's clear that her strategic mindset aligns perfectly with Serina’s mission to innovate in drug delivery.
Leadership Transition at Serina
Additionally, Serina announced the departure of Steven Mintz from its Board of Directors. CEO Ledger acknowledged Mintz's contributions during the company's evolution from a private entity to being publicly traded, emphasizing his role in preparing the company for future growth.
Understanding the POZ Platform Potential
The proprietary POZ Platform technology utilized by Serina is centered on an innovative synthetic polymer named poly(2-oxazoline), known for its water-soluble characteristics and low viscosity. This technology is designed to enhance drug loading capabilities and precision in the rate of drug release via subcutaneous injection. Such advancements are vital for addressing the challenges associated with pharmacokinetics, like toxicity and short half-life issues.
Serina's approach aims to refine treatment options for drugs that traditionally have narrow therapeutic windows, ensuring that they can achieve stable and effective blood levels. This is particularly important for therapeutic agents that, while effective, often face limitations in current delivery methods.
Broadening Applications of POZ Technology
The versatility of Serina’s POZ technology allows for the exploration of various applications across a wide range of drug types and medical indications. The company is on the lookout for opportunities to advance the use of its POZ platform through out-licensing, partnerships, or co-development agreements. Notably, Serina has established a non-exclusive license agreement with Pfizer, Inc., enabling the application of Serina’s POZ polymer technology in lipid nanoparticle drug delivery formulations.
About Serina Therapeutics
Serina Therapeutics is at the forefront of clinical-stage biotechnology, focused on developing a range of wholly owned drug products aimed at treating neurological diseases and other significant health issues. The potential of Serina’s POZ platform extends across diverse modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs). Operating out of Huntsville, Alabama, Serina is strategically located within the HudsonAlpha Institute of Biotechnology.
Frequently Asked Questions
What is the POZ Platform?
The POZ Platform is a proprietary drug delivery technology developed by Serina Therapeutics that utilizes a synthetic polymer to enhance the delivery of therapeutics.
Who is Karen J. Wilson?
Karen J. Wilson is a newly appointed board member of Serina with extensive experience in financial leadership within the biotech sector.
Why did Steven Mintz leave the board?
Steven Mintz departed from the board to facilitate new leadership dynamics as Serina continues its growth as a public company.
How does Serina ensure drug efficacy?
Serina focuses on using its POZ technology to maintain stable therapeutic levels and to enhance drug performance and safety profiles.
What indications is Serina targeting?
Serina is primarily targeting neurological diseases, among other medical applications, through its advancing drug product candidates.
